Proton pump inhibitors: Key ingredients in helicobacter pylori eradication treatment

Frontiers of Gastrointestinal Research

Volumn 32, Issue 1, 2013, Pages 59-67

  Sugiyama, Toshiro ^a,b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b TOYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; BISMUTH; CIPROFLOXACIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; DOXYCYCLINE; ERYTHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; NITROIMIDAZOLE; OFLOXACIN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SITAFLOXACIN; TETRACYCLINE;

ANTIBACTERIAL ACTIVITY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COLITIS; DIARRHEA; DIZZINESS; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; LIVER DYSFUNCTION; METALLIC TASTE; NAUSEA; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN DEGRADATION; STOMACH ACID SECRETION; STOMACH JUICE; TASTE DISORDER;

EID: 84888858731     PISSN: 03020665     EISSN: 16623754     Source Type: Book Series    
DOI: 10.1159/000350631     Document Type: Article

References (31)

1. Hentschel E, Brandstatter G, Dragosics B, et al: Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. Gastroenterology 1997; 113: 1082-1086.
2. Leodolter A, Kulig M, Brasch H, et al: A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori -associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15: 1949-1958.
3. Miwa H, Sakaki N, Sugiyama T, et al: Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4,940 patients. Helicobacter 2004; 9: 9-16.
4. Fukase K, Kato M, Kikuchi S, et al: Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-397.
5. Wotherspoon AC, Doglioni C, Diss TC, et al: Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori . Lancet 1993; 342: 575-577.
6. Nakamura S, Sugiyama T, Matsumoto T, et al: Longterm clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multi-center cohort follow-up study of 420 patients in Japan. Gut 2012; 61: 507-513 .
7. Malfertheiner P, Megraud F, O'Morain C, et al: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781.
8. Asaka M, Kato M, Sugiyama T, et al: Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20.
9. Ford AC, Delaney BC, Forman D, et al: Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004; 99: 1833-1855.
10. Logan RPH, Gummett PA, Misiewicz JJ, et al: One week's anti-Helicobacter pylori treatment for duodenal ulcer. Gut 1994; 35: 15-18.
11. Labenz J, Beker JA, Dekker CP, et al: Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxicillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. Aliment Pharmacol Ther 1997; 11: 515-522.
12. Lind T, Veldhuyzen ZS, Unge P, et al: Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH1 study. Helicobacter 1996; 1: 138-144.
13. Lind T, Megraud F, Unge P, et al: The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-253.
14. Malfertheiner P, Bayerdörffer E, Diete U, et al: The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13: 703-712.
15. Zanten SJ, Bradette M, Farley A, et al: The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13: 289-295.
16. Iwahi T, Satoh H, Nakao M: Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori . Antimicrob Agents Chemother 1991; 35: 490-496.
17. Mainguet P, Delmee M, Debongnie JP: Omeprazole, Campylobacter pylori, and duodenal ulcer. Lancet 1989; 2: 289-290.
18. Nagata K, Satoh H, Iwahi T, et al: Proton inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori : unique action selective for H. pylori cells. Antimicrob Agents Chemother 1993; 37: 769-774.
19. Mauch F, Bode G, Malfertheiner P: Identification and characterization of an ATPase system of Helicobacter pylori and effect of proton pump inhibitors. Am J Gastroenterol 1993; 88: 1801-1802.
20. Grayson ML, Elipoulos GM, Ferraro MJ, et al: Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8: 888-889.
21. McNulty CA, Dent JC, Ford GA, et al: Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother 1988; 22: 729-738.
22. Kudo T, Fujinami H, Sugiyama T, et al: Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study. Helicobacter 2012; 17: 277-281.
23. Sugiyama T, Furuyama S, Awakawa T, et al: Local immune response in gastric mucosa to Helicobacter pylori infection with and without intestinal metaplasia. Eur J Gastroenterol Hepatol 1993; 5: 119-122.
24. Kuwayama H, Asaka M, Sugiyama T, et al: Rabeprazole-based eradication therapy for Helicobacter pylori : a large-scale study in Japan. Aliment Pharmacol Ther 2007; 25: 1105-1113.
25. Furuta T, Shirai N, Ohashi K, et al: Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori . Methods Find Exp Clin Pharmacol 2003; 25: 131-143.
26. Hokari K, Sugiyama T, Kato M, et al: Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther 2001; 15: 1479-1484.
27. Abelo A, Anderson TB, Antonsson M, et al: Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 966-972.
28. Saitoh T, Fukushima Y, Otsuka H, et al: Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 16: 1811-1817.
29. Isomoto H, Furusu H, Morikawa T, et al: 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment Pharamacol Ther 2000; 14: 1619-1623.
30. Calvet X, Garcia N, Lopez T, et al: A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:603-609.
31. Murakami K, Furuta T, Ando T, et al: Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol 2013, E-pub ahead of print.